news
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza,…
20 January 2022 | By Victoria Rees (Drug Target Review)
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.